Nohla is a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases. The company’s lead product, dilanubicel (NLA101), is a universal, off-the-shelf stem and progenitor cell therapy designed to provide short-term bone marrow function, while also providing long-term immunologic benefits with the potential for improved survival.
In May 2018, Nohla announced the closing of a $45 million Series B financing. In this round, Fidelity Management and Research Company and Celgene Corporation (Nasdaq: CELG) joined existing investors, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners, who also participated in the financing. To date, the company has raised approximately $100 million.
The Series B financing allows the company to build on the progress it is making in advancing its lead clinical product, dilanubicel, toward potential regulatory approvals in multiple regions. The additional funding will also fuel further research of Nohla’s other off-the-shelf discovery programs in support of its mission to provide meaningful therapies to patients with significant unmet needs.